What the latest quarter means for Veracyte stock

Veracyte (VCYT) drew fresh attention after reporting second quarter results that included revenue of $150.32 million and net income of $25.49 million, alongside a raised full year 2026 revenue outlook to a range of $590 million to $596 million.

Veracyte's second quarter swing to profitability and higher 2026 revenue guidance have arrived after a mixed stretch for the share price, with a 30 day share price return down 18.78% but a 90 day share price return up 16.96% and a 1 year total shareholder return of 65.31%. This points to momentum that has cooled recently but remains strong over a longer horizon.

If Veracyte's latest results have you thinking about where else growth stories may emerge in healthcare diagnostics, it could be worth scanning a wider field of AI driven medical companies through the 43 healthcare AI stocks

The share price has cooled after strong 1 year gains, while Veracyte now reports profit and higher 2026 guidance. Does that recent pullback still leave the risk reward skewed toward buyers at the current valuation?

Most Popular Narrative: 18.2% Undervalued

Veracyte's most followed narrative points to a fair value of $56.55 against the last close of $46.27, which frames the stock as undervalued and leans heavily on product and pipeline execution to support that gap.

Pipeline momentum with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

Want to see what sits behind that pipeline driven upside case? The narrative leans on steady revenue expansion, firm profit margins, and a rich earnings multiple to reach its fair value, and explores how those assumptions stack together and what would need to go right.

The narrative applies a 7.16% discount rate and builds to 2029 earnings and revenue assumptions that support a projected P/E just under 50x, higher than the current P/E for the wider US Biotechs industry. It also factors in only moderate margin compression and gradual share count growth, which keeps earnings per share moving higher in the model and helps justify the $56.55 fair value even though analysts are not in tight agreement on the exact earnings path.

Result: Fair Value of $56.55 (UNDERVALUED)

However, Veracyte's heavy reliance on Afirma and Decipher, along with potential reimbursement or regulatory setbacks, could quickly challenge the upbeat, pipeline‑driven narrative.

Another view on Veracyte's valuation

The narrative built around Veracyte leans on future earnings and a rich P/E multiple. Yet today the stock trades on a P/E of 32.5x, well above both the US Biotechs industry at 17.2x and its own fair ratio of 18.9x. That premium suggests investors are already paying up heavily for the story. How comfortable are you with that valuation gap if sentiment cools?

Next Steps

The mixed signals around Veracyte's valuation and growth story mean sentiment will not be the same for every investor. Take a moment to review the company data, pressure test the upside case, and then weigh those 3 key rewards.

Looking for more investment ideas beyond Veracyte?

If Veracyte has sharpened your focus on quality opportunities, do not leave it there. Use the Simply Wall Street Screener to spot other stocks that fit your style and risk comfort.

• Target dependable income streams by reviewing companies in the 9 dividend fortresses that may suit a yield focused approach.
• Hunt for quality at a reasonable price by scanning the 51 high quality undervalued stocks that combine fundamentals with potential upside.
• Prioritise resilience by checking the 83 resilient stocks with low risk scores that may better match a capital preservation mindset.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.